EP 73: GLP 1s - One Class of Drugs with Many Different Names
Treating Multiple Diseases–Which Indication is Right for You?
In this episode, Dr. Jeremy Pettus and Dr. Steve Edelman go head-to-head in a friendly face-off between two of the most talked-about medications in diabetes and weight management: Ozempic and Mounjaro. Both are part of the powerful GLP-1 class, but which one might be better for you? From A1C reduction and weight loss to heart and kidney protection, ease of use, side effects, and insurance coverage—Drs. E & P walk you through a category-by-category comparison. They bring the clinical data and their own real-world patient experience to help you understand the key differences (and similarities) between these leading therapies. Whether you’re managing type 2 diabetes, living with type 1, or exploring options for weight loss, this episode is designed to help you make an informed decision with your healthcare provider.
My Endo put me on Mounjaro last June. I was 142 lbs and my A1C was 6.8. Fast forward to today (endo of April 2025). I’ve lost 65 lbs and my last 2 A1C’s were 5.7! I was on the Tandem Mobi and will now be going off that and going back to Lantus. My daily insulin intake has gone from 72 units a day to 13! She wanted to take me off the pump at the end of the Feb, but we were just getting ready to leave for AZ for the month of March and I didn’t want to make any changes until I got back. Mounjaro has had such a huge impact on my quality of life.
That’s awesome! Thanks for sharing, and so glad it’s helped you!
Excellent podcast. You guys are the best.
Thanks Ruth…appreciate it!